PROBLEM: Pulsed field ablation is now FDA-approved for atrial fibrillation across multiple systems, but treatment records vary, making it hard to compare outcomes, energy doses, and recurrence across sites.
SOLUTION: A standard treatment record for every PFA procedure: system used, energy parameters, lesion set, acute success, complications, and recurrence at follow-up, recorded in a common format so outcomes can be compared across the approved systems.
EVIDENCE BASIS: DOCUMENTED — Abbott Volt PFA FDA approved Dec 22, 2025 (VOLT-AF IDE, 392 patients); Boston Scientific FARAPULSE expanded labeling July 7, 2025 (ADVANTAGE AF, 260 patients, 85.3% symptomatic recurrence-free); Medtronic PulseSelect FDA approved Dec 2023. Research note D6, D7, D8.
| Idea priority | Low |
| Needed By | Not sure -- Just thought it was cool |
By clicking the "Post Comment" or "Submit Idea" button, you are agreeing to the IBM Ideas Portal Terms of Use.
Do not place IBM confidential, company confidential, or personal information into any field.